<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04825548</url>
  </required_header>
  <id_info>
    <org_study_id>PTS-NOPHOALL2008</org_study_id>
    <nct_id>NCT04825548</nct_id>
  </id_info>
  <brief_title>Post-thrombotic Syndrome After Deep Venous Thrombosis (DVT) in Patients Treated According to the NOPHO ALL2008 Protocol</brief_title>
  <official_title>Post-thrombotic Syndrome After Deep Venous Thrombosis (DVT) in Patients Treated According to the NOPHO ALL2008 Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute lymphoblastic leukemia (ALL) is the most common malignant disease in childhood. Today&#xD;
      more than 90% of children and 75% of adults (18-45 years) survive ALL. The enzyme&#xD;
      Asparaginase (Asp) is an indispensable part of the multiagent treatment of ALL.&#xD;
&#xD;
      Treatment related severe acute toxicities are common. Especially in teenagers and adults,&#xD;
      thromboembolism is one of the most common acute toxicities and may result in post thrombotic&#xD;
      syndrome (PTS) or pulmonary hypertension. The knowledge about these late effects is limited,&#xD;
      including for ALL patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with post thrombotic syndrome</measure>
    <time_frame>01112020-01022023</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Post Thrombotic Syndrome</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Examination of patients with previous DVT</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients between 1.0-45 years of age and diagnosed with DVT and PE during treatment on&#xD;
        the NOPHO ALL2008 protocol. In this period, 115 patients were diagnosed with DVT&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Treated on the ALL2008 protocol for ALL. Had a DVT on treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Death&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Birgitte K Albertsen, MD</last_name>
    <phone>20224643</phone>
    <email>biralber@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Merete E Dam, MD</last_name>
    <phone>27268201</phone>
    <email>meretdam@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <state>VÃ¦lg En Region, Stat Eller Provins.</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merete Dam. MD. Phd student Aarhus University H Denmark</last_name>
      <phone>27268201</phone>
      <email>meretdam@rm.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>March 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Birgitte Klug Albertsen</investigator_full_name>
    <investigator_title>M.D., PhD, Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Postthrombotic Syndrome</mesh_term>
    <mesh_term>Postphlebitic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

